Comparative Pharmacology
Head-to-head clinical analysis: SODIUM SULFATE POTASSIUM SULFATE AND MAGNESIUM SULFATE versus XPHOZAH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SODIUM SULFATE POTASSIUM SULFATE AND MAGNESIUM SULFATE versus XPHOZAH.
SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE vs XPHOZAH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Osmotic laxative; induces bowel cleansing by retaining water in the intestinal lumen via osmotic effects, increasing intraluminal pressure and stimulating peristalsis.
XPHOZAH (tenapanor) is a sodium-hydrogen exchanger 3 (NHE3) inhibitor. It acts locally in the gastrointestinal tract to inhibit NHE3, reducing sodium and phosphate absorption, leading to decreased serum phosphate levels.
Oral: 3 packets (each containing 17.5g sodium sulfate, 3.13g potassium sulfate, and 1.6g magnesium sulfate) dissolved in water as a single dose, or as two doses: first packet in evening, second and third packets next morning. Route: oral. Frequency: single or split dose for colonoscopy preparation.
10 mg orally three times daily (TID) with or without food.
None Documented
None Documented
Not applicable as intact drug; component electrolytes have variable half-lives: sulfate ~12-24 hours; potassium and magnesium are actively regulated with redistribution half-lives of minutes to hours.
Terminal elimination half-life is approximately 14 days, supporting monthly subcutaneous dosing for sustained serum phosphate reduction.
Primarily renal: sulfate ions are excreted unchanged in urine; minimal biliary/fecal elimination (<5%).
Primarily eliminated in feces (approximately 92%) as unchanged drug; renal excretion is negligible (<1%).
Category C
Category C
Laxative
Laxative